Kenvue Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; the filing also provides unaudited fourth-quarter results. Kenvue became fully independent from Johnson & Johnson (J&J) in August 2023. Because the pre-April 4, 2023 financial statements reflect the former J&J business on a carve-out basis, historical results may not represent the costs or results of a standalone company.
Business context and financial performance
Kenvue is a global consumer health company with three segments: Self Care; Skin Health and Beauty; and Essential Health. Its portfolio includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID Brand, Aveeno and Zyrtec. Approximately half of 2023 sales were generated outside North America.
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Net sales | $15.444 billion | $14.950 billion | +3.3%; organic growth +5.0% |
| Gross profit / margin | $8.643 billion / 56.0% | $8.285 billion / 55.4% | Margin +60 bps |
| Operating income | $2.512 billion | $2.675 billion | -6.1% |
| Net income | $1.664 billion | $2.064 billion | -19.4% |
| Diluted EPS | $0.90 | $1.20 | Down from prior year |
| Operating cash flow | $3.168 billion | $2.525 billion | +25.5% |
| Capital expenditures | $469 million | $375 million | — |
Gross margin improved through pricing/mix and supply-chain savings, partly offset by inflation and transactional currency effects. SG&A rose 9.0% to $6.141 billion, with standalone-company and transition-service costs and $468 million of non-recurring Separation-related costs (up from $213 million). Interest expense, net was $250 million, compared with none in FY2022. Approximate operating and net margins, calculated from reported figures, were 16.3% and 10.8%, respectively.
Operating cash flow less capital expenditures was approximately $2.699 billion, calculated from reported amounts. Cash and equivalents were $1.382 billion at year-end. Total debt was $8.286 billion, including $7.687 billion of long-term debt and $599 million of commercial paper; the $4.0 billion revolving facility was undrawn. Management said cash, operating cash flow and available borrowing capacity should be sufficient for current obligations for at least the next 12 months. The company reported compliance with debt covenants.
Segments and period comparisons
| Segment | FY2023 sales | Sales growth | Adjusted operating income | Change |
|---|---|---|---|---|
| Self Care | $6.451 billion | +7.0% reported; +8.4% organic | $2.299 billion | +10.1% |
| Skin Health and Beauty | $4.378 billion | +0.6% reported; +1.8% organic | $679 million | -4.1% |
| Essential Health | $4.615 billion | +1.0% reported; +3.6% organic | $1.011 billion | -9.0% |
Organic growth was led by pricing/mix, while total volume declined 2.7%. Self Care volumes grew 1.3%; Skin Health and Beauty and Essential Health volumes fell 4.8% and 6.0%, respectively. Unfavorable currency translation reduced reported sales by $253 million. For Q4 FY2023, net sales were $3.666 billion versus $3.767 billion a year earlier; net income was $327 million versus $361 million, and diluted EPS was $0.17 versus $0.21.
Liquidity, capital allocation and outlook
FY2023 operating cash flow benefited from working-capital movements, including higher payables and accrued liabilities, lower inventory and lower receivables. Investing cash outflow was $488 million. Financing cash outflow was $2.527 billion, including a $13.788 billion distribution to J&J and $766 million of dividends, partly offset by IPO and debt proceeds. Kenvue paid two 2023 quarterly dividends of $0.20 per share and announced a further $0.20 dividend for February 2024. It repurchased 350,000 shares for $7 million under a 27 million-share authorization.
The filing provides no formal earnings or sales guidance. Management expects non-recurring Separation costs to continue through at least FY2024 and identifies capital expenditures as a key 2024 cash requirement. It cites persistent inflation, elevated energy and labor costs, supply-chain pressures, competitive markets and changing consumer preferences. Management reported no goodwill impairment in FY2023.
Risks, contingencies and unusual items
- Separation execution: Kenvue continues to build standalone functions and separate IT systems, and relies on J&J transition services and manufacturing arrangements that expire at varying times. Replacement arrangements could cost more or disrupt supply. Certain asset, liability and contract transfers remain incomplete.
- Product and litigation exposure: FDA’s advisory committee concluded that available scientific data did not support oral phenylephrine’s effectiveness at the recommended dose as a nasal decongestant; FDA had not decided on regulatory action. Consumer and securities litigation followed, and the company said potential losses could not be reliably estimated.
- Talc: J&J retained and agreed to indemnify U.S. and Canadian talc-related liabilities, but Kenvue remains responsible for talc-related liabilities involving products sold outside those markets. Kenvue cannot assure J&J will fully satisfy its indemnity. Talc-based Johnson’s Baby Powder was discontinued globally in 2023.
- Other claims: In February 2024, a federal court entered judgment for J&J Consumer Inc. and other sellers in favor of defendants in most pending acetaminophen MDL cases; other actions remain. The filing also describes Zantac, sunscreen benzene, environmental and other proceedings. For certain matters, potential losses beyond accruals cannot be estimated.
- Independence and tax: Historical allocations may differ from actual standalone costs. Separation agreements impose tax-related restrictions through August 23, 2025, and Kenvue has joint and several liability with J&J for U.S. federal consolidated taxes for periods when it was in J&J’s group.
- Other principal risks: brand and product safety concerns, private-label competition, retailer concentration (one customer represented about 12% of sales; top 10 about 41%), inflation and foreign exchange, supply disruption, cybersecurity and privacy, regulation, and substantial indebtedness.
Most important facts for investors to verify
- Whether underlying sales and volume trends improve, particularly in Skin Health and Beauty and Essential Health, and whether pricing/mix can offset volume and cost pressure.
- How standalone costs and J&J transition-service and manufacturing costs evolve after the Separation, and whether remaining transfers and IT separation are completed smoothly.
- Debt service, commercial-paper refinancing, cash generation and dividend capacity; total debt was $8.286 billion at year-end.
- Developments in oral phenylephrine regulation and litigation, talc claims outside the U.S. and Canada, and the adequacy and collectability of J&J indemnities.
- Internal-control readiness: the 10-K did not include management’s assessment or auditor attestation on internal control over financial reporting because of the newly public company transition period. Disclosure controls were reported effective, and the financial statements received an unqualified audit opinion.